Evotec Se Revenue Growth Rates (EVO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Evotec Se  (NASDAQ: EVO)
 

EVO's Revenue Growth by Quarter and Year

Evotec Se's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EVO Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 882.98
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 882.98

EVOs Annual Revenue
Evotec Se's Revenue in the fiscal year 2025 $ 882.98 millions
Evotec Se's Revenue in the fiscal year 2024 $ 892.60 millions
Evotec Se's Revenue in the fiscal year 2023 $ 875.20 millions
Evotec Se's Revenue in the fiscal year 2022 $ 841.62 millions
Evotec Se's Revenue in the fiscal year 2021 $ 692.20 millions




EVO Revenue fourth quarter 2025 Y/Y Growth Comment
Evotec Se reported decrease in Revenue in the fourth quarter 2025 by -1.08% to $ 882.98 millions, from the same quarter in 2024.
The decrease in the fourth quarter 2025 Evotec Se's Revenue compares unfavorably to the Company's average Revenue increase of 12.79%.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue growth. While Evotec Se' s Revenue decline of -1.08% ranks overall at the positon no. 558 in the fourth quarter 2025.


EVO Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December -1.08 % 1.99 % 3.99 % 21.59 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   -1.08 % 1.99 % 3.99 % -

Financial Statements
Evotec Se's fourth quarter 2025 Revenue $ 882.98 millions EVO's Income Statement
Evotec Se's fourth quarter 2024 Revenue $ 892.60 millions Quarterly EVO's Income Statement


EVO Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   -1.08 % 1.99 % 3.99 % -


Back to EVO Growth rate Comparisons >> Back to EVO Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #135
Overall #558

Revenue Y/Y Growth Statistics
High Average Low
21.59 % 12.79 % 3.99 %
(Dec 31 2022)   (Dec 31 2023)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #135
Overall #558
Revenue Y/Y Growth Statistics
High Average Low
21.59 % 12.79 % 3.99 %
(Dec 31 2022)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Evotec Se's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


EVO's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


EVO's IV. Quarter Q/Q Revenue Comment


Evotec Se's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
Cumulative Revenue 12 Months Ending $ 882.98 $ 892.60 $ 875.20 $ 841.62 $ 0.00
Y / Y Revenue Growth (TTM) -1.08 % 1.99 % 3.99 % 21.59 % -
Year on Year Revenue Growth Overall Ranking # 558 # 612 # 744 # 0 # 0
Seqeuential Revenue Change (TTM) -1.08 % 1.99 % 3.99 % 21.59 % -
Seq. Revenue Growth (TTM) Overall Ranking # 558 # 612 # 744 # 0 # 0


Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2025 Evotec Se reported a decrease in Revenue by -1.08% year on year, to $883 millions, compare to the 1.99% growth at Dec 31 2024.

In the Healthcare sector 134 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 558, from total ranking in previous quarter at 612.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 60
Healthcare Sector # 135
Overall # 558

Revenue TTM Y/Y Growth Statistics
High Average Low
21.59 %
 12.79 %
3.99 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 60
Sector # 135
S&P 500 # 558
Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2025 Evotec Se reported a decrease in Revenue by -1.08% year on year, to $883 millions, compare to the 1.99% growth at Dec 31 2024.

In the Healthcare sector 134 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 558, from total ranking in previous quarter at 612.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 60
Healthcare Sector # 135
Overall # 558

Revenue TTM Y/Y Growth Statistics
High Average Low
21.59 %
12.79 %
3.99 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 60
Sector # 135
S&P 500 # 558




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EVO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Ardent Health Inc -0.08%$ -0.075 millions
Chemed Corporation-0.10%$ -0.103 millions
Embecta Corp -0.15%$ -0.153 millions
Bruker Corporation-0.24%$ -0.245 millions
Vaso Corporation-0.38%$ -0.376 millions
Bio techne Corp-0.54%$ -0.542 millions
Lftd Partners Inc -0.76%$ -0.763 millions
Xtant Medical Holdings Inc -0.82%$ -0.821 millions
Charles River Laboratories International inc -0.83%$ -0.830 millions
Koninklijke Philips Nv-1.04%$ -1.038 millions
Evotec Se-1.08%$ -1.078 millions
Pfizer Inc-1.16%$ -1.160 millions
Adapthealth Corp -1.21%$ -1.209 millions
Avantor Inc -1.36%$ -1.364 millions
Alpha Teknova Inc -1.42%$ -1.422 millions
Skinhealth Systems Inc -1.57%$ -1.569 millions
Pediatrix Medical Group Inc -1.71%$ -1.711 millions
Integra Lifesciences Holdings Corp-1.74%$ -1.744 millions
Edap Tms Sa-1.78%$ -1.783 millions
Vivos Therapeutics Inc -2.18%$ -2.178 millions
Absci Corp-2.26%$ -2.256 millions
Prestige Consumer Healthcare Inc -2.30%$ -2.303 millions
Perrigo Company Plc-2.52%$ -2.521 millions
Bionano Genomics Inc -2.60%$ -2.597 millions
Haemonetics Corporation-2.64%$ -2.636 millions
Amphastar Pharmaceuticals Inc -2.79%$ -2.790 millions
Strata Skin Sciences Inc-2.97%$ -2.966 millions
Plus Therapeutics Inc -3.19%$ -3.187 millions
Harvard Bioscience Inc -3.23%$ -3.226 millions
Brookdale Senior Living Inc -3.44%$ -3.439 millions


About Evotec Se Revenue Growth Rates (EVO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Evotec Se (CIK 1412558).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-040767
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Evotec Se’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.